Whitepapers

Pharmaceutical Executive: Apr 29, 2015
When it comes to supporting the clinical and marketing objectives of a pharmaceutical franchise, removing potential barriers for patients and providers is a primary focus for any brand team. How are manufacturers using hub model programs to maximize brand access and adherence?
Pharmaceutical Executive: Apr 16, 2015
Hubs provide an array of services and solutions to multiple stakeholders throughout a patient’s treatment. What should manufacturers look for when hiring a hub?
Pharmaceutical Executive: Apr 12, 2015
Drug development has never before been so difficult, time consuming and expensive. Accuracy in clinical trials, therefore, is a priority. However, suboptimal adherence is prevalent in ambulatory trials, in which outpatients are responsible for taking the drug according to the protocol-specified dosing regimen. Unfortunately, most methods for measuring medication adherence are inaccurate, which can result in costly phase III failures. This whitepaper focuses on a proven exception—automatic adherence measurement through electronic compilation of drug dosing histories. Electronic measurement enables a better understanding of drug safety and efficacy data, improving the likelihood of a successful trial outcome and more informed development decisions, leading to faster speed to commercialization.
Mar 23, 2015
By studying the companies that succeed, Oracle has identified four areas where they have created advantages not related to product innovation. These areas are ones that any company can emulate and implement every day. The metrics provide insight into top-level corporate and operational health.
Mar 23, 2015
Pharmaceutical marketers need to find a new way to offer modern, personalized marketing content that will help them get their message across to the right people, but remain HIPAA compliant at the same time.
Mar 23, 2015
Social media provides an opportunity for Life Sciences companies to publish controlled content and messaging, drive inbound traffic to websites, and respond to negative press in a timely and deliberate manner.
Pharmaceutical Executive: Mar 18, 2015
CEOs of generic companies report they are considering a spectrum of solutions to bridge the revenue gap, but perhaps none are more valid than the U.S. FDA’s 505(b)(2) approval pathway, which can offer accelerated approval, reduced development costs, lower risk and, in certain cases, market exclusivity. In this podcast, readers will get an understanding of 505(b)(2), why developers are choosing it, how products are identified and models for development.
Pharmaceutical Executive: Mar 16, 2015
This white paper is about why—and how—a commitment to functional integration can help management navigate the often-unforgiving transition from registration to the real-world battle for clinical acceptance and market share. It draws on a recent Executive Roundtable hosted by Pharmaceutical Ex- ecutive and facilitated by Editor-in-Chief William Looney that included UMT Consulting Group along with four big Pharma practitioners in the art of commercial effectiveness
Pharmaceutical Executive: Feb 02, 2015
This whitepaper provides an overview and best practices for success when implementing access programs for patients with unmet medical needs. Programs described expanded access, compassionate use, named patient programs which are allowed by regulatory authorities around the world.
Pharmaceutical Executive: Jan 12, 2015
The ability to capture, connect, and extract value from laboratory asset data is critical to a company's ability to run its business efficiently. Decision makers are hard pressed to answer fundamental questions about laboratory assets: asset census and density, laboratory service event information, instrument downtime and asset utilization. Given this reality, knowing what your optimized asset footprint should be, much less the real total cost of ownership is a challenge. "Bringing Business Analytics to the Lab" discusses overcoming these challenges.